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Chronic Methylglyoxal Infusion by Minipump Causes
Pancreatic b-Cell Dysfunction and Induces Type 2
Diabetes in Sprague-Dawley Rats
Arti Dhar, Indu Dhar, Bo Jiang, Kaushik M. Desai, and Lingyun Wu
OBJECTIVE—The incidence of high dietary carbohydrate-
induced type 2 diabetes is increasing worldwide. Methylglyoxal
(MG) is a reactive glucose metabolite and a major precursor of
advanced glycation end products (AGEs). MG levels are elevated
in diabetic patients. We investigated the effects of chronic
administration of MG on glucose tolerance and b-cell insulin se-
creting mechanism in 12-week-old male Sprague-Dawley rats.
RESEARCH DESIGN AND METHODS—MG (60 mg/kg/day) or
0.9% saline was administered by continuous infusion with a
minipump for 28 days. We performed glucose and insulin tol-
erance tests and measured adipose tissue glucose uptake and
insulin secretion from isolated pancreatic islets. We also used
cultured INS-1E cells, a pancreatic b-cell line, for molecular stud-
ies. Western blotting, quantitative PCR, immunohistochemistry,
and transferase-mediated dUTP nick-end labeling (TUNEL) assay
were performed.
RESULTS—In rats treated with MG and MG + L-buthionine sulf-
oximine (BSO), MG levels were signiﬁcantly elevated in plasma,
pancreas, adipose tissue, and skeletal muscle; fasting plasma glu-
cose was elevated, whereas insulin and glutathione were re-
duced. These two groups also had impaired glucose tolerance,
reduced GLUT-4, phosphoinositide-3-kinase activity, and insulin-
stimulated glucose uptake in adipose tissue. In the pancreatic
b-cells, MG and MG + BSO reduced insulin secretion, pancreatic
duodenal homeobox-1, MafA, GLUT-2, and glucokinase expres-
sion; increased C/EBPb, nuclear factor-kB, MG-induced AGE, N
´-
carboxymeythyllysine, and receptor for AGEs expression; and
caused apoptosis. Alagebrium, an MG scavenger and an AGE-
breaking compound, attenuated the effects of MG.
CONCLUSIONS—Chronic MG induces biochemical and molec-
ularabnormalities characteristicof type2 diabetesandisa possible
mediator of high carbohydrate-induced type 2 diabetes. Diabetes
60:899–908, 2011
T
ype 2 diabetes is characterized by hyperglyce-
mia, insulin resistance, and progressive decrease
in insulin secretion from the pancreas (1). A
genetic predisposition has been found in many
patients. More recently there has been a staggering in-
creasing in the incidence of type 2 diabetes, many of the
cases being reported in children. This explosive increase
is attributed to a diet high in carbohydrates, fat, and a sed-
entary lifestyle (2–6). Oxidative stress is associated with di-
abetes and has been proposed as one of the causative factors
(7,8). An increase in oxidative stress caused the insulin re-
sistance of Zucker obese rats to progress to type 2 diabetes
in 1 week (9).
Methylglyoxal (MG) is a reactive dicarbonyl metabolite
of mainly glucose metabolism (10). MG reacts with pro-
teins to form advanced glycation end products (AGEs)
(10,11), which are implicated in the pathogenesis of vas-
cular complications of diabetes (11,12). Plasma MG levels
in healthy humans are 1 mmol/L or less and are elevated
two- to fourfold in diabetic patients (13,14). Under physi-
ological conditions, the glyoxalase system degrades MG
into D-lactate with the help of reduced glutathione (GSH)
(10,14) and keeps plasma MG levels at approximately
1 mmol/L or less (13,14). Incubation of vascular smooth
muscle cells with 25 mmol/L glucose or fructose for 3 h
signiﬁcantly increases MG production and oxidative stress
(15). In vitro incubation of MG with insulin modiﬁes the
insulin molecule and impairs insulin-mediated glucose
uptake in adipocytes (16). Incubation of cultured L6 muscle
cells with MG (2.5 mmol/L) for 30 min impaired insulin
signaling (17). However, the in vitro studies cannot es-
tablish whether MG is the cause of diabetes or an effect of
diabetes.
The molecular mechanisms of high dietary carbohydrate-
induced type 2 diabetes are not clear. It is possible that
high carbohydrate-induced chronic elevation of MG causes
cumulative pathologic changes that contribute to the de-
velopment of insulin resistance and type 2 diabetes. We
have recently shown that acute MG (50 mg/kg iv) admin-
istered to 12-week-old male Sprague-Dawley (SD) rats
caused glucose intolerance and reduced adipose tissue
insulin-stimulated glucose uptake (18). Here we report the
results of a comprehensive study on the effects of chron-
ically administered MG on in vivo glucose tolerance, adi-
pose tissue glucose uptake and insulin secretion from
isolated pancreatic islets, and the underlying molecular
mechanisms. We administered MG by continuous infusion
with minipump for 28 days, a method used for the ﬁrst time
to administer MG.
RESEARCH DESIGN AND METHODS
Animals.AllanimalprotocolswereapprovedbytheAnimalCareCommittee of
the University ofSaskatchewan. Male SD rats, 11 weeksold, from Charles River
Laboratories (Quebec, Canada) were treated according to guidelines of the
Canadian Council on Animal Care.
MG (40% solution) was administered to12-week-old maleSD rats for 28days
by means of an osmotically driven infusion minipump (Alzet 2ML4, Durect
Corporation, Cupertino, CA) implanted subcutaneously on the back. This pump
releases a continuous small amount of MG into the body at a rate of 2.5 mL/h,
amounting to 60 mg/kg/day. There was no inﬂammatory inﬁltrate or response
in the animals with the infusion or the pump implantation. Control rats were
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ORIGINAL ARTICLEadministered 0.9% saline (2.5 mL/h) by means of subcutaneously implanted
pump. GSH plays a key role in degrading MG. We also treated two groups of
rats with L-buthionine sulfoximine (BSO), an inhibitor of g-glutamyl cysteine
synthetase (19), which prevents GSH synthesis, decreases MG degradation,
and increases MG levels. Alagebrium (AGA) is a MG scavenger and an AGE-
breaking compound (18,20).
After one week of acclimatization, the rats were divided into the following
treatment groups (n = 6 each): 1) control – 0.9% saline, 2) MG (60 mg/kg/day),
3) MG (60 mg/kg/day) + ALA (30 mg/kg/day in drinking water), 4) MG (60 mg/
kg/day) + BSO (30 mg/kg/day in drinking water), 5) BSO alone (30 mg/kg/day
in drinking water), and 6) ALA alone (ALA, 30 mg/kg/day in drinking water).
All of the treatments were for 28 days. ALA alone had no effect.
Biochemical parameters. Blood was collected from anesthetized rats from
different treatment groups; the plasma was separated and analyzed for fasting
basal levels of glucose, insulin, free fatty acids, total cholesterol, triglycerides,
HDL, creatine kinase (CK), creatinine, alanine aminotransferase (ALT), and
aspartate aminotransferase (AST). The free fatty acid levels in plasma samples
of rat were measured using an ELISA kit (Cusabio Biotech) following the
manufacturer’s instruction.
Oral glucose tolerance test. After overnight fasting, an oral glucose toler-
ance test (GTT) was performed. In brief, the trachea, left jugular vein, and right
carotid artery were cannulated in anesthetized rats. After a basal blood sample
was collected, an oral glucose load (1 g/kg) was given with a stomach tube.
Furtherbloodsampleswerecollectedat15,30,60,and120minfromthecarotid
artery. Plasma glucose levels were determined using a glucose assay kit
(BioAssay Systems, Hayward, CA), and insulin levels were measured with a rat
insulin ELISA assay kit (Mercodia, Winston Salem, NC).
Insulin release from freshly isolated pancreatic islets. The pancreatic
islets were freshly isolated from SD rats as described previously (21) and in the
Supplementary Data. Insulin release was determined after incubation of the
islets with the test compounds.
Glucose uptake. Adipose tissue glucose uptake was performed as described
(22) and in the Supplementary Data. [
3H]-2-Deoxy glucose (0.1 mCi/500 mL)
was used for uptake experiments.
MG assay. MG was measured by a speciﬁc and sensitive high-performance
liquid chromatography (HPLC) method as described previously and in the
Supplementary Data (23).
Measurement of reduced GSH levels. The GSH levels in the plasma and
organs were determined by derivation with 5,50-dithio-bis (2-nitrobenzoic acid)
and reverse-phase HPLC using ultra-violet detection, as described previously
(24).
Isolation of plasma membrane for GLUT4. Adipose tissue plasma mem-
brane was isolated with an isolation kit (BioVision, MountainView, CA) as
described in the Supplementary Data.
INS-1E cell culture experiments. INS-1E cells (a pancreatic islet b-cell line,
a generous gift from Dr. C. B. Wollheim, Geneva, Switzerland) were cultured
as described in the Supplementary Data. These cells were used to determine
insulin secretion, peroxynitrite levels, ATP-sensitive K
+ channel (KATP)_chan-
nel currents, intracellular calcium levels and phosphoinositide 3-kinase (PI3K)
activity as described in the Supplementary Data.
Western immunoblotting. Isolated pancreas and adipose tissue were subjected
to Western blotting as described previously (21,22) and in the Supplementary Data.
Real-time quantitative PCR. RNA was isolated from the pancreas using RNA
isolation kit (Qiagen Sciences, Germantown, MD). The total RNA was reverse-
transcribedintriplicateusing RevertAid HMinus M-MuLV reversetranscriptase
(MBI, Fermentas Burlington, ON, Canada) in the presence of 53 RT buffer
(MBI, Fermentas), random primer (Invitrogen, Carlsbad, CA), and dNTP
mixture (Amersham, Pittsburgh, PA) at 42°C for 50 min, followed by 72°C for
10 min. The predesigned primers for pancreatic duodenal homeobox-1 (PDX-1)
and MafA were from Qiagen Sciences (Germantown, MD). The real-time PCR
was carried out in an iCycler iQ apparatus (Bio-Rad, Life Science Research,
Hercules, CA). All PCRs were triplicated and run for 45 cycles at 95°C for 20 s,
62°C for 1 min, and 72°C for 30 s. After cycling, melting curves of the PCR
p r o d u c t sw e r ea c q u i r e db ys t e p w i s ei n c r e a s eo ft h et e m p e r a t u r ef r o m6 2 °t o9 5 ° C .
Determination of cell apoptosis. The transferase-mediated dUTP nick-end
labeling (TUNEL) assay kit (Roche Diagnostics, Indianapolis, IN) was used as
described in the Supplementary Data. DNA was isolated from pancreas using
DNA extraction kit (R & D Systems, Minneapolis, MN). Equal amount and
concentration (1 mg) of DNA was loaded on 1% agarose gel and run at 100 V
for 2 h. The gel was visualized on Syngene bio-imaging system (Syngene,
Frederick, MD) (25).
Chemicals and statistical analysis. All chemicals were of analytical grade.
MG and o-phenylenediamine (o-PD) were purchased from Sigma-Aldrich,
Oakville, ON, Canada. Alagebrium (formerly known as ALT-711) was a gen-
erous gift from Synvista Therapeutics (Montvale, NJ). Data are expressed as
mean 6 SEM and analyzed using one-way ANOVA and post hoc Bonferroni’s
test. P value less than 0.05 was considered signiﬁcant.
RESULTS
Chronic MG treatment signiﬁcantly alters metabolic
characteristics of SD rats. MG, MG + BSO, and BSO
treatment for four weeks signiﬁcantly increased fasting
plasma glucose, free fatty acids, total cholesterol, and tri-
glycerides (Table 1) and decreased fasting plasma insulin
and HDL (Table 1) levels compared with the control group.
There was no signiﬁcant difference in the body weight
between the treatment groups (Table 1) and markers in-
dicating tissue or organ damage such as serum CK for
muscle damage, creatinine for kidney function, and ALT
and AST for liver damage (Table 1). Pretreatment with
ALA (30 mg/kg/day) signiﬁcantly attenuated MG-induced
changes in the metabolic parameters (Table 1).
MG and GSH levels are different among treatment
groups. MG-, MG + BSO-, and BSO-treated groups had
signiﬁcantly elevated plasma, pancreas, adipose tissue, and
skeletal muscle MG levels compared with control (Fig. 1A–D)
TABLE 1
Plasma levels of several parameters in SD rats treated with MG
Parameter Control MG MG + BSO BSO MG + ALA ALA
Body weight (g) 558 6 18 556 6 9 582 6 13 536 6 33 588 6 7 543 6 21
Fasting plasma glucose (mg/dL) 89 6 6 121 6 6* 139 6 7*** 116 6 10* 95 6 98 9 6 8
Fasting plasma insulin (mg/L) 1.2 6 0.1 0.5 6 0.1** 0.3 6 0.02*** 0.7 6 0.1* 1 6 0.2† 1.25 6 0.06
Plasma free fatty acids (mg/L) 393 6 41 619 6 21*** 890 6 21***††† 601 6 32*** 405 6 20††† 389 6 22†††
Total cholesterol (mmol/L) 1.8 6 0.1 2.4 6 0.05*** 2.8 6 0.05***†† 2.1 6 0.1**‡‡‡ 1.9 6 0.03†† —
HDL (mmol/L) 1.2 6 0.05 0.7 6 0.06** 0.46 6 0.05***† 0.78 6 0.1**‡ 1.0 6 0.07†—
Triglycerides (mmol/L) 0.2 6 0.03 0.5 6 0.04*** 0.7 6 0.02***†† 0.4 6 0.05**‡‡‡ 0.3 6 0.02†† —
Creatinine (mmol/L) 55 6 56 6 6 67 5 6 85 8 6 55 2 6 2 —
CK (U/L) 315 6 20 365 6 25 378 6 23 355 6 21 332 6 15 —
ALT (U/L) 60 6 10 65 6 97 1 6 10 63 6 75 9 6 8 —
AST (U/L) 46 6 55 0 6 85 6 6 94 8 6 44 5 6 6 —
Values are means 6 SE of n = 6 experiments. Either 0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion with a sub-
cutaneous osmotic pump for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA (30 mg/kg/day in drinking water; MG + ALA and
ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was administered to some groups of rats. The
control group received only saline (0.9% by pump). After 28 days, basal fasting plasma levels of substances listed in the table were measured.
*P , 0.05, **P , 0.01, ***P , 0.001 vs. respective control group; †P , 0.05, ††P , 0.01, †††P , 0.001 vs. respective MG group; ‡P , 0.05,
‡‡‡P , 0.001 vs. respective MG + BSO group.
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ALA group (Fig. 1A–D). MG levels were higher in plasma
and tissues in the MG + BSO group compared with MG and
BSO alone groups (Fig. 1A–D). MG, MG + BSO, and BSO
treatment signiﬁcantly reduced GSH levels in the plasma,
pancreas, and skeletal muscle compared with control (Fig.
1E, F, and H). ALA pretreatment attenuated the decrease
in GSH induced by MG (Fig. 1E, F, and H). Adipose tissue
FIG. 1. MG levels are elevated, and reduced GSH levels are decreased in SD rats chronically treated with MG. Either 0.9% saline or MG (60 mg/kg/
day) was delivered by continuous infusion with a subcutaneous osmotic minipump for 28 days to all groups of rats (n = 6 each). The MG scavenger
ALA (30 mg/kg/day in drinking water) (MG + ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water) (MG + BSO and BSO) was
administered to some groups of rats. The control group received only saline (0.9% by pump). After 28 days, MG and GSH levels were determined by
HPLC in plasma (A and E) and organs (B–D and F–H). *P < 0.05, **P < 0.01, ***P < 0.001 vs. respective control; †P < 0.05, ††P < 0.01, †††P <
0.001 vs. respective MG group; ‡P < 0.05, ‡‡P < 0.01, ‡‡‡P < 0.001 vs. respective MG + BSO group.
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skeletal muscle (Fig. 1F–H).
Chronic MG impairs glucose tolerance in SD rats. MG
and MG + BSO treatment signiﬁcantly impaired in vivo
glucose tolerance determined after an oral glucose load in
SD rats (Fig. 2A). Plasma glucose levels were signiﬁcantly
higher in the MG and MG + BSO group compared with
control even 2 h after the glucose load. ALA pretreatment
attenuated the impaired glucose tolerance induced by MG
(Fig. 2A).
MG- and MG + BSO-treated groups had signiﬁcantly
lower plasma insulin levels compared with the control
group in the oral GTT (Fig. 2B). The plasma insulin levels
were lower in the MG + BSO group compared with the MG
alone group. The plasma insulin levels were signiﬁcantly
lower than control even 2 h after the glucose load in the
MG and MG + BSO groups. ALA pretreatment attenuated
the reduced insulin levels induced by chronic MG treatment
(Fig. 2B). Chronic MG and MG + BSO also impaired the
insulin tolerance test in rats, which was attenuated by ALA
cotreatment with MG (Supplementary Fig. 1S).
Chronic MG treatment reduces glucose uptake, plasma
membrane GLUT4 expression, and PI3K activity in
adipose tissue. Insulin-stimulated glucose uptake was
signiﬁcantly decreased in adipose tissue freshly isolated
from rats treated with MG or MG + BSO compared with
those from control rats, attenuated by ALA cotreatment
with MG (Fig. 3A). To understand the mechanism of MG-
induced impaired glucose tolerance and reduced glucose
FIG. 2. The oral glucose tolerance test is impaired in SD rats chronically
treated with MG. Either 0.9% saline or MG (60 mg/kg/day) was de-
livered by continuous infusion with a subcutaneous osmotic minipump
for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA
(30 mg/kg/day in drinking water; MG + ALA) or GSH synthesis inhibitor
BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was ad-
ministered to some groups of rats. The control group received only
saline (0.9% by pump). After 28 days, the rats were fasted overnight,
anesthetized, and cannulated. A basal 0-min blood sample was taken
from the carotid artery. After that an oral glucose load (1 g/kg body
weight) was administered and blood samples were collected from the
carotid artery at different times up to 120 min. Plasma was separated
and analyzed for glucose (A) and insulin levels (B) following the glu-
cose load. The inset box shows the area under curve (AUC) values for
different groups. *P < 0.05, **P < 0.01, ***P < 0.001 vs. respective
control at the same time point; †P < 0.05, ††P < 0.01, †††P < 0.001 vs.
respective MG group at the same time point; ‡‡P < 0.01, ‡‡‡P < 0.001
vs. respective MG + BSO group at the same time point.
FIG. 3. Adipose tissue glucose uptake and plasma membrane GLUT4
protein are reduced in chronic MG-treated SD rats. Either 0.9% saline
or MG (60 mg/kg/day) was delivered by continuous infusion with
a subcutaneous osmotic minipump for 28 days to all groups of rats (n =
6 each). The MG scavenger ALA (30 mg/kg/day in drinking water; MG +
ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water;
MG + BSO and BSO) was administered to some groups of rats. The
control group received only saline (0.9% by pump). After 28 days, the
rats were fasted overnight, and abdominal visceral adipose tissue (A)
was removed and tested for insulin-stimulated glucose uptake in vitro.
B: The adipose tissue was also subjected to Western blotting to deter-
mine the plasma membrane (PM) and total GLUT4 protein as described
in RESEARCH DESIGN AND METHODS. The plasma membrane was isolated as
described in the Supplementary Data. **P < 0.01, ***P < 0.001 vs. con-
trol; †P < 0.05 vs. MG group, ‡‡‡P < 0.001 vs. MG + BSO group.
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plasma membrane was determined. There was a signiﬁ-
cant decrease in plasma membrane GLUT4 in MG- and
MG + BSO-treated rats (Fig. 3B), attenuated by ALA
cotreatment with MG. BSO alone also reduced plasma
membrane GLUT4 (Fig. 3B). There was no change in
insulin receptor (IR) and insulin receptor substrate (IRS-1)
protein expression, but phosphorylation of IRS-1 was re-
duced by MG and MG + BSO (Supplementary Fig. 2S). MG
and MG + BSO also reduced activity of PI3K in adipose
tissue (Supplementary Fig. 2S). ALA attenuated the effects
of MG in adipose tissue.
Chronic MG treatment reduces total insulin content
and glucose-stimulated insulin release from pancreas.
The pancreatic insulin content was signiﬁcantly reduced in
MG- and MG + BSO-treated groups compared with control
(Fig. 4). ALA attenuated the reduction in insulin content
by MG (Fig. 4). Moreover, basal and glucose-stimulated
insulin release from isolated pancreatic islets was sig-
niﬁcantly reduced in MG and MG + BSO groups compared
with control (Fig. 5A). BSO alone also signiﬁcantly reduced
glucose-stimulated insulin secretion compared with control
but less than MG + BSO group (Fig. 5A). ALA signiﬁcantly
attenuated MG-induced decrease in glucose-stimulated in-
sulin release from the pancreatic islets (Fig. 5A).
Effects of chronic MG on insulin synthesis/secretion
pathway in pancreas. To determine the cause of MG-
induced reduction of basal plasma insulin level and glucose–
stimulated insulin release from pancreatic islets, we looked
at the molecular mechanisms of insulin synthesis and se-
creting pathways. GLUT2 is the transporter for glucose
entry into islet cells. PDX-1 (also known as insulin pro-
moter factor 1) and MafA are positive regulators, whereas
C/EBPb is a negative regulator of insulin gene transcrip-
tion. There was a signiﬁcant decrease in GLUT2 (Fig. 5B),
PDX-1, and MafA protein expression in pancreas from
MG- and MG + BSO-treated rats (Fig. 6A). There was also
a signiﬁcant decrease in mRNA expression of PDX-1 and
MafA in MG- and MG + BSO-treated rats as compared with
control (Fig. 6B). ALA attenuated the decrease in GLUT2
(Fig. 5B), PDX-1, and MafA protein and mRNA induced by
MG (Fig. 6). At the same time, there was a signiﬁcant
increase in C/EBPb protein expression and mRNA in MG-
and MG + BSO-treated rats, which was attenuated by ALA
cotreatment with MG (Fig. 6A and B). In the isolated islets,
MG and MG + BSO also decreased the protein expression
of GLUT2, glucokinase, PDX-1, and MafA and increased
the protein expression of C/EBPb, nuclear factor kB( S u p -
plementary Fig. 3S), and the receptor for AGE (RAGE)
(Supplementary Fig. 4S).
MG reduces insulin secretion and increases reactive
oxygen species in cultured INS-1E cells, a pancreatic
b-cell line. In INS-1E-cultured cells, there was no change
in glucose-induced intracellular calcium levels between
different treatments (Supplementary Fig. 5S, B). MG, MG +
BSO, and BSO increased reactive oxygen species pro-
duction (Supplementary Fig. 5S, A), which were attenuated
by cotreatment of MG with the superoxide dismutase-
mimetic, tempol, or ALA. However, tempol could not atten-
uate the reduced insulin secretion induced by MG, whereas
FIG. 4. Pancreatic insulin content is reduced in SD rats chronically
treated with MG. Either 0.9% saline or MG (60 mg/kg/day) was de-
livered by continuous infusion with a subcutaneous osmotic minipump
for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA
(30 mg/kg/day in drinking water; MG + ALA) or GSH synthesis inhibitor
BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was ad-
ministered to some groups of rats. The control group received only
saline (0.9% by pump). After 28 days, the rats were fasted overnight,
and the pancreas was removed and evaluated for insulin content. *P <
0.05, **P < 0.01 vs. control.
FIG. 5. Pancreatic GLUT2 and insulin release from isolated pancreatic
islets are reduced in SD rats chronically treated with MG. Either 0.9%
saline or MG (60 mg/kg/day) was delivered by continuous infusion with
a subcutaneous osmotic minipump for 28 days to all groups of rats (n =
6 each). The MG scavenger ALA (30 mg/kg/day in drinking water; MG +
ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water;
MG + BSO and BSO) was administered to some groups of rats. The
control group received only saline (0.9% by pump). After 28 days, the
rats were fasted overnight, and the pancreatic islets (A) were isolated
as described in RESEARCH DESIGN AND METHODS. Glucose-stimulated insulin
secretion was evaluated in the isolated islets in vitro. B: The pancreatic
tissue was removed and processed for determination of GLUT2 protein
expression by Western blotting. *P < 0.05, ***P < 0.001 vs. respective
control; ††P < 0.01, †††P < 0.001 vs. respective MG group, ‡‡‡P < 0.001
vs. respective MG + BSO group.
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not affect KATP channel activity in INS-1E cells (Supple-
mentary Fig. 6S).
Chronic MG treatment induces apoptosis of pancreatic
b-cells and increases AGE formation. After chronic MG
and MG + BSO administration, there was signiﬁcant DNA
fragmentation (Fig. 7A) and signiﬁcant positive BrdUTP
staining, indicating apoptosis (Fig. 7B) of pancreatic b-cells
compared with control, which was attenuated by ALA
cotreatment with MG (Fig. 7A and B). BSO alone also
partially induced apoptosis (Fig. 7B) but had no effect on
DNA fragmentation (Fig. 7A). Chronic MG and MG + BSO
also increased MG-induced AGE, N
´-carboxymethyllysine
(CML) formation in pancreas (Supplementary Fig. 7S).
DISCUSSION
In the current study, we report for the ﬁrst time that MG
administered by continuous infusion with a minipump for
28 days to SD rats induces metabolic, biochemical, and
molecular abnormalities characteristic of type 2 diabetes.
The most notable change induced by MG was an elevation
of fasting plasma glucose and reduction of insulin level
accompanied by a signiﬁcantly impaired oral GTT (Figs. 1
and 2). The adipose tissue from MG-treated rats showed
signiﬁcantly reduced insulin–stimulated glucose uptake,
reduced plasma membrane GLUT4 protein, unchanged IR
and IRS-1 protein, and reduced phosphorylation of IRS-1
and PI3K activity. There was signiﬁcant pancreatic islet
b-cell dysfunction in MG- and MG + BSO-treated rats. Thus
FIG. 6. Insulin gene transcription factors PDX-1 and MafA protein expression and mRNA are reduced; and CCAAT/Enhancer Binding Protein b
(C/EBPb) protein expression and mRNA are enhanced in Sprague-Dawley rats chronically treated with MG. Either 0.9% saline or MG (60 mg/kg/day)
was delivered by continuous infusion with a subcutaneous osmotic minipump for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA
(30 mg/kg/day in drinking water; MG + ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was admin-
istered to some groups of rats. The control group received only saline (0.9% by pump). After 28 days, the pancreatic tissue was removed and
processed for determination of PDX-1, MafA, and C/EBPb protein expression by Western blotting (A). B: PDX-1, MafA, and C/EBPb mRNA were
also determined by RT-PCR in pancreatic tissue isolated from groups of rats described above. *P < 0.05, **P < 0.01, ***P < 0.001 vs. respective
control; †P < 0.05, ††P < 0.01 vs. respective MG group; ‡P < 0.05 vs. respective MG + BSO group.
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freshly isolated pancreatic islets, GLUT2 protein level was
decreased, pancreatic insulin content was lower, and
protein as well as mRNA expression of insulin gene tran-
scription factors PDX-1 and MafA were signiﬁcantly
reduced, whereas for C/EBPb they were increased in MG-
and MG + BSO-treated rats. In the pancreatic islets, RAGE
protein and the MG-induced AGE, CML, were increased by
MG, MG + BSO, and BSO. The deleterious effects of MG
were attenuated by the MG scavenger ALA (18,20).
To the best of our knowledge, MG has not been pre-
viously administered chronically by continuous infusion,
which would mimic the supposedly continuous production
of MG in the body and avoid the excessive peaks in plasma
associated with repeated intraperitoneal or subcutaneous
injections. The plasma levels of MG were signiﬁcantly
FIG. 7. Chronic MG induces apoptosis in pancreatic islets in SD rats. Either 0.9% saline or MG (60 mg/kg/day) was delivered by continuous infusion
with a subcutaneous osmotic minipump for 28 days to all groups of rats (n = 6 each). The MG scavenger ALA (30 mg/kg/day in drinking water; MG +
ALA) or GSH synthesis inhibitor BSO (30 mg/kg/day in drinking water; MG + BSO and BSO) was administered to some groups of rats. The control
group received only saline (0.9% by pump). After 28 days, DNA (A) was isolated and run on agarose gel to evaluate DNA integrity. B: A part of the
pancreas was removed and ﬁxed in 4% paraformaldehyde. The tissue was processed for sectioning and stained for the TUNEL assay. Big black
arrows show the pancreatic islet; small black arrows show brown staining of apoptotic cells. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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control (Fig. 1A), similar to a range reported in diabetic
animals and patients (13,14,22). MG levels were also sig-
niﬁcantly higher in the pancreas, adipose tissue, and
skeletal muscle, which can explain the metabolic changes
observed in these organs/tissues. GSH levels were reduced
in the plasma, pancreas, adipose tissue, and skeletal mus-
cle. GSH plays a central role in the degradation of MG
by binding MG and making it available to the glyoxalase
enzymes (10,19,26). A reduction in GSH would decrease
MG degradation, increase its levels, and set up a vicious
cycle. This was observed in groups of rats treated with the
GSH synthesis inhibitor BSO (19). The inhibition of GSH
synthesis with BSO and the consequent further elevation
of MG levels could be either because of an increase in
endogenous MG levels, which add to the exogenously ad-
ministered MG, or it can be because of inhibition of deg-
radation of exogenously administered MG, or both effects.
Thus organ/tissue speciﬁc elevation of endogenous MG
levels may have different effects in some instances, com-
pared with an increase in MG levels induced by exogenous
administration. MG itself has been shown to reduce GSH
levels (Fig. 1, E–H) (23,26). Pancreatic b-cells have low
levels of GSH and antioxidant capacity compared with other
tissues, making it more susceptible to oxidative damage
(27). GSH levels in pancreas were lower compared with
skeletal muscle (Fig. 1F and H).
The fasting elevated plasma glucose and low insulin
levels (Table 1) are features of type 2 diabetes (1), which is
characterized by insulin resistance, impaired b-cell func-
tion, and glucose regulation, leading to b-cell failure. In the
case of type 2 diabetes, functional b-cells vary in numbers,
with gradual progressive apoptosis in the advanced stages.
In the early type 2 diabetes, the insulin resistance, char-
acterized by defects in the insulin signaling pathway (28),
elicits a compensatory increase in pancreatic insulin se-
cretion and higher than normal plasma insulin levels. As
the disease progresses, insulin release from the pancreas
becomes reduced, because of apoptosis and decrease in
b-cell numbers in the later stages, resulting in lower than
normal plasma insulin levels and hyperglycemia (1,29).
The apoptosis of pancreatic islet b-cells in type 2 diabetes
differentiates it from the necrosis of b-cells seen in type 1
diabetes. Thus insulin in the circulation can be either high
or low depending on the stage of diabetes. High fructose
typically induces insulin resistance with higher plasma
insulin levels (22). Thus fructose probably induces milder
changes after nine weeks of treatment and the pancreas
still can produce more insulin in response to resistance,
whereas exogenous MG probably induces more severe
changes, which include progressive apoptosis that char-
acterizes the later stages of type 2 diabetes, and reduces
the insulin secreting capacity of the pancreas and lower
plasma insulin levels.
The oral GTT revealed signiﬁcantly impaired glucose
tolerance and reduced insulin-response to the glucose
load. An impaired GTT is a feature of the prediabetic in-
sulin resistance as well as type 2 diabetes. One reason for
the elevated plasma glucose levels could be reduced re-
sponse of insulin sensitive tissues to insulin because of
defects in one or more steps of the insulin signaling
pathway. We have shown that there is reduced GLUT4 in
plasma membrane (Fig. 3), reduced phosphorylation of
IRS-1, and reduced activity of PI3K (Supplementary Fig. 2S).
In vitro studies have shown that incubation of cultured 3T3-
L1 adipocytes with MG reduced glucose uptake, decreased
insulin-induced IRS-1 tyrosine phosphorylation, and de-
creased the activity of PI3K (17,22). The Zucker diabetic rat,
a genetic model, has a defect of glucose transport in muscle
(30). We have recently shown that a single dose of MG
(50 mg/kg iv) given to SD rats causes reduced membrane
GLUT4 and IRS-1 phosphorylation in adipose tissue (18).
The reduced fasting plasma insulin and the reduced in-
sulin response to the glucose load could be the result of
pancreatic islet dysfunction induced by MG. The total
pancreatic insulin content was reduced in rats treated with
MG and MG + BSO (Fig. 4). This is likely because of re-
duced transcription of insulin synthesis as indicated by
reduced mRNA and protein levels of the insulin gene
promoters PDX-1 and MafA induced by MG in the pan-
creas (Fig. 6) and isolated islets (Supplementary Fig. 3S).
PDX-1 is an essential regulator of both pancreatic exocrine
and endocrine cell development. Inactivation of PDX-1 in
the b-cells impairs b-cell function and causes diabetes
(31–33). Similarly, MafA activates insulin as well as glu-
cagon gene expression in the pancreatic islet b2 and
a-cells, respectively (34). The expression of PDX-1 and
MafA is reduced in diabetes, resulting in decreased insulin
synthesis and secretion (35).
MG and MG + BSO upregulated C/EBPb in pancreas
(Fig. 6) and in isolated islets (Supplementary Fig. 3S),
which can also be responsible for the reduced insulin
levels in these rats because C/EBPb is a repressor of in-
sulin gene transcription in b-cells and in diabetic animal
models (36). MG- and MG + BSO-treated groups also had
reduced basal and glucose-stimulated insulin secretion
from isolated pancreatic islets and also from cultured INS-
1E cells. These results support our previous study (18).
GLUT2 acts as a glucose sensor and sends a signal inside
the cell to cause insulin secretion when the extracellular
glucose concentration increases (37). GLUT2 is reduced in
animal models of type 2 diabetes (38). The reduced se-
cretion of insulin in the MG and MG + BSO groups of rats
can be partly explained by signiﬁcantly reduced membrane
GLUT2 and glucokinase in the pancreas (Fig. 5B, Supple-
mentary Fig. 3S).
In type 1 diabetes, there is b-cell death, whereas type 2
diabetes is characterized by gradual apoptosis of islet
b-cells, which ultimately results in reduced insulin secre-
tion (29,33,39,40). MG- and MG + BSO-induced DNA frag-
mentation and caused apoptosis in pancreatic cells (Fig.
7A and B). Reduced islet number would also contribute to
reduced pancreatic insulin content and insulin secretion
(Figs. 4 and 5A).
To further elucidate the role of MG in the metabolic and
biochemical abnormalities described above, one group of
rats was treated with MG + ALA. We have recently shown
that ALA attenuates acute MG-induced glucose intolerance
in SD rats (18). Thus ALA has acute MG scavenging action
besides being a known AGEs breaker (20,41,42). The at-
tenuation of chronic MG-induced deleterious effects by
ALA strongly supports the role of MG as an inducer of
insulin resistance and b-cell dysfunction.
The deleterious effects of MG were not random because
there were no signiﬁcant changes in the levels of bio-
markers such as CK, an indicator of muscle damage, cre-
atinine, an indicator of kidney function, and ALT and AST,
which are enzyme markers for liver damage (Table 1). The
reason for increased plasma levels of free fatty acids, total
cholesterol and triglycerides, and reduced levels of HDL
induced by MG and MG + BSO treatment (Table 1) is not
known and requires further investigations.
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etary carbohydrate may cause daily abnormal elevations
of MG levels, which can cause cumulative pathologic
changes in the islet b-cell insulin secreting machinery and
in the insulin signaling pathway in tissues, such as the
skeletal muscle and adipose tissue. The severity and the
time course of progression of these pathologic changes to
type 2 diabetes may depend on the overall health of the
individual, any underlying oxidative stress, GSH levels, and
antioxidant defenses.
In summary, we have shown for the ﬁrst time that
chronic administration of MG to SD rats induces abnor-
malities in glucose homeostasis and insulin secretion. The
direct involvement of MG in these deleterious effects is
supported by the GSH synthesis inhibitor BSO, which
caused a further increase in MG levels when combined
with MG treatment and attenuation of the deleterious
effects of MG by the MG scavenger ALA. Our results sug-
gest that MG is a possible mediator of high glucose-
induced insulin resistance and type 2 diabetes that is
becoming a serious health problem in the Western world
(3–6). Further studies may show that speciﬁc and safe MG
scavengers could be useful in preventing high glucose-
induced insulin resistance and type 2 diabetes.
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